Atypical Chronic Myelogenous Leukemia, BCR-ABL1 Negative: Diagnostic Criteria and Treatment Approaches

Atypical chronic myelogenous leukemia (aCML), BCR/ABL1 negative is a rare myelodysplastic/myeloproliferative neoplasm, usually manifested with hyperleukocytosis without monocytosis or basophilia, organomegaly, and marked dysgranulopoiesis. In this review, we will discuss the classification and diagn...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Panagiotis T. Diamantopoulos, Nora-Athina Viniou
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	atypical chronic myelogenous leukemia myelodysplastic syndrome/myeloproliferative neoplasm diagnostic criteria treatment molecular characterization Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/738dd1804ff64cda93ea9196008307a2
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:738dd1804ff64cda93ea9196008307a2
record_format	dspace
spelling	oai:doaj.org-article:738dd1804ff64cda93ea9196008307a22021-11-17T05:41:08ZAtypical Chronic Myelogenous Leukemia, BCR-ABL1 Negative: Diagnostic Criteria and Treatment Approaches2234-943X10.3389/fonc.2021.722507https://doaj.org/article/738dd1804ff64cda93ea9196008307a22021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fonc.2021.722507/fullhttps://doaj.org/toc/2234-943XAtypical chronic myelogenous leukemia (aCML), BCR/ABL1 negative is a rare myelodysplastic/myeloproliferative neoplasm, usually manifested with hyperleukocytosis without monocytosis or basophilia, organomegaly, and marked dysgranulopoiesis. In this review, we will discuss the classification and diagnostic criteria of aCML, as these have been formulated during the past 30 years, with a focus on the recent advances in the molecular characterization of the disease. Although this entity does not have a definitive molecular profile, its molecular characterization has contributed to a better understanding and more accurate classification and diagnosis of aCML. At the same time, it has facilitated the identification of adverse prognostic factors and the stratification of patients according to their risk for leukemic transformation. What is more, the molecular characterization of the disease has expanded our therapeutic choices, thoroughly presented and analyzed in this review article.Panagiotis T. DiamantopoulosNora-Athina ViniouFrontiers Media S.A.articleatypical chronic myelogenous leukemiamyelodysplastic syndrome/myeloproliferative neoplasmdiagnostic criteriatreatmentmolecular characterizationNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENFrontiers in Oncology, Vol 11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	atypical chronic myelogenous leukemia myelodysplastic syndrome/myeloproliferative neoplasm diagnostic criteria treatment molecular characterization Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	atypical chronic myelogenous leukemia myelodysplastic syndrome/myeloproliferative neoplasm diagnostic criteria treatment molecular characterization Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Panagiotis T. Diamantopoulos Nora-Athina Viniou Atypical Chronic Myelogenous Leukemia, BCR-ABL1 Negative: Diagnostic Criteria and Treatment Approaches
description	Atypical chronic myelogenous leukemia (aCML), BCR/ABL1 negative is a rare myelodysplastic/myeloproliferative neoplasm, usually manifested with hyperleukocytosis without monocytosis or basophilia, organomegaly, and marked dysgranulopoiesis. In this review, we will discuss the classification and diagnostic criteria of aCML, as these have been formulated during the past 30 years, with a focus on the recent advances in the molecular characterization of the disease. Although this entity does not have a definitive molecular profile, its molecular characterization has contributed to a better understanding and more accurate classification and diagnosis of aCML. At the same time, it has facilitated the identification of adverse prognostic factors and the stratification of patients according to their risk for leukemic transformation. What is more, the molecular characterization of the disease has expanded our therapeutic choices, thoroughly presented and analyzed in this review article.
format	article
author	Panagiotis T. Diamantopoulos Nora-Athina Viniou
author_facet	Panagiotis T. Diamantopoulos Nora-Athina Viniou
author_sort	Panagiotis T. Diamantopoulos
title	Atypical Chronic Myelogenous Leukemia, BCR-ABL1 Negative: Diagnostic Criteria and Treatment Approaches
title_short	Atypical Chronic Myelogenous Leukemia, BCR-ABL1 Negative: Diagnostic Criteria and Treatment Approaches
title_full	Atypical Chronic Myelogenous Leukemia, BCR-ABL1 Negative: Diagnostic Criteria and Treatment Approaches
title_fullStr	Atypical Chronic Myelogenous Leukemia, BCR-ABL1 Negative: Diagnostic Criteria and Treatment Approaches
title_full_unstemmed	Atypical Chronic Myelogenous Leukemia, BCR-ABL1 Negative: Diagnostic Criteria and Treatment Approaches
title_sort	atypical chronic myelogenous leukemia, bcr-abl1 negative: diagnostic criteria and treatment approaches
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/738dd1804ff64cda93ea9196008307a2
work_keys_str_mv	AT panagiotistdiamantopoulos atypicalchronicmyelogenousleukemiabcrabl1negativediagnosticcriteriaandtreatmentapproaches AT noraathinaviniou atypicalchronicmyelogenousleukemiabcrabl1negativediagnosticcriteriaandtreatmentapproaches
_version_	1718425866492444672

Atypical Chronic Myelogenous Leukemia, BCR-ABL1 Negative: Diagnostic Criteria and Treatment Approaches

Ejemplares similares